Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.77
-0.06 (-0.68%)
Apr 29, 2026, 3:35 PM EDT - Market open
Company Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
The company is headquartered in San Diego, California.
Kura Oncology, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 260 |
| CEO | Troy Wilson |
Contact Details
Address: 4930 Directors Place, Suite 500 San Diego, California 92121 United States | |
| Phone | 858 500 8800 |
| Website | kuraoncology.com |
Stock Details
| Ticker Symbol | KURA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422143 |
| CUSIP Number | 50127T109 |
| ISIN Number | US50127T1097 |
| Employer ID | 61-1547851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, Chief Executive Officer and President |
| Kathleen Ford | Chief Operating Officer |
| Brian T. Powl M.B.A., M.S. | Chief Commercial Officer |
| Thomas Doyle | Senior Vice President of Finance and Accounting |
| Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer |
| Greg Mann | Senior Vice President of Investor Relations and Corporate Affairs |
| Teresa Brophy Bair Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
| Dr. Mollie Leoni M.D. | Chief Medical Officer |
| Samir Vattompadam M.S. | Senior Vice President of Global Program Leadership |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2026 | ARS | Filing |
| Apr 10, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Jan 29, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 144 | Filing |